What talks are relevant to me?

It is not intended that all registrants will attend all presentations. Joining the presentation live gives the opportunity to contribute to the discussion by submitting questions to the session host. Presentations/discussions will be recorded/published on our website for one month after the event to ensure you can still access content for presentations you were unable to see live.

Listed below is groupings of presentations different target groups could be interested in to assist in confirming your schedule;

Introductory

• Introduction to mRNA delivery technologies – Nov 17 12:30-13:00
• Evolution of mRNA/DNA vaccines and the future – Nov 17 16:00-17:00
• Viral vectors as gene therapies and vaccines – Nov 18 12:00-13:00

Public/political

• acceptance of gene delivery medicines – Nov 16 12:00-13:00
• perspectives in rapid gene delivery technologies – Nov 16 13:00-14:00
• data ownership and sharing implications – Nov 16 15:00-16:00
• opportunities in industrial scale manufacture  – Nov 17 14:00-15:00
• future manufacture capabilities in Sweden – Nov 18 14:00-15:00

Patient

• perspectives in gene delivery technologies – Nov 16 13:00-14:00
• data ownership and sharing implications – Nov 16 15:00-16:00

Regulatory

• classifications and implications – Nov 16 14:00-15:00
• mRNA quality, manufacture and regulatory – Nov 17 13:00-14:00
• adenovirus quality, manufacture and regulatory – Nov 18 13:00-14:00
• data ownership and sharing implications – Nov 16 15:00-16:00
• Accreditation of assays and laboratories – Nov 16 16:00-17:00

mRNA medicines/research

• introduction to delivery technologies – Nov 17 12:30-13:00
• quality, manufacture and regulatory aspects – Nov 17 13:00-14:00
• the founding of Moderna and mRNA vaccine – Nov 17 15:00-16:00
• Evolution of mRNA/DNA vaccines and the future – Nov 17 16:00-17:00
• industrial manufacture of gene delivery medicines – Nov 17 14:00-15:00

Viral vector/adenovirus medicines/research

• Viral vectors as gene therapies and vaccines – Nov 18 12:00-13:00
• quality, manufacture and regulatory aspects – Nov 18 13:00-14:00
• industrial manufacture of gene delivery medicines – Nov 17 14:00-15:00

Manufacture

• mRNA quality, manufacture and regulatory – Nov 17 13:00-14:00
• adenovirus quality, manufacture and regulatory – Nov 18 13:00-14:00
• industrial manufacture of gene delivery medicines – Nov 17 14:00-15:00
• future manufacture capabilities in Sweden – Nov 18 14:00-15:00

Clinical

• patient perspectives in gene delivery technologies – Nov 16 13:00-14:00
• data ownership and sharing implications – Nov 16 15:00-16:00
• Accreditation of assays and laboratories – Nov 16 16:00-17:00
• Clinical performance of VEGF mRNA therapeutic for heart failure – Nov 17 16:00-16:30
• Implementation of new therapeutic modalities – Nov 18 11:00-12:00

Pharmacy

• Accreditation of assays and laboratories – Nov 16 16:00-17:00
• mRNA quality, manufacture and regulatory – Nov 17 13:00-14:00
• Implementation of new therapeutic modalities – Nov 18 11:00-12:00
• adenovirus quality, manufacture and regulatory – Nov 18 13:00-14:00

Industry/Commercialisation

• Accreditation of assays and laboratories – Nov 16 16:00-17:00
• industrial manufacture of gene delivery medicines – Nov 17 14:00-15:00
• the founding of Moderna and mRNA vaccine – Nov 17 15:00-16:00
• Implementation of new therapeutic modalities – Nov 18 11:00-12:00